- Trials with a EudraCT protocol (336)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
336 result(s) found for: Drug culture.
Displaying page 2 of 17.
EudraCT Number: 2004-004573-29 | Sponsor Protocol Number: DORI-06 | Start Date*: 2005-01-21 | |||||||||||
Sponsor Name:Peninsula Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Multicenter, Phase 3 Study to Confirm the Safety and Efficacy of Intravenous Doripenem in Complicated Lower Urinary Tract Infection or Pyelonephritis | |||||||||||||
Medical condition: Complicated Lower Urinary Tract Infection or Pyelonephritis MedDRA: Lower urinary tract infection or pyelonephritis (10024981 and/or 10059517) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003170-33 | Sponsor Protocol Number: INS-312 | Start Date*: 2016-03-14 | |||||||||||
Sponsor Name:Insmed Inc. | |||||||||||||
Full Title: An Open-Label Safety Extension Study to a Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections caused by Mycobacter... | |||||||||||||
Medical condition: Nontuberculous Mycobacterial (NTM) Lung Infections caused by Mycobacterium avium complex (MAC) that are refractory to treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) AT (Completed) ES (Completed) PL (Completed) NL (Completed) SE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003571-56 | Sponsor Protocol Number: APX001-201 | Start Date*: 2018-12-17 | |||||||||||
Sponsor Name:Amplyx Pharmaceuticals, Inc. | |||||||||||||
Full Title: An Open-Label Study to Evaluate the Efficacy and Safety of APX001 in Non-Neutropenic Patients with Candidemia, with or without Invasive Candidiasis, Inclusive of Patients with Suspected Resistance ... | |||||||||||||
Medical condition: Treatment of non-neutropenic subjects with candidemia – inclusive of those subjects with suspected or confirmed antifungal-resistant candidemia with or without invasive candidiasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006041-14 | Sponsor Protocol Number: FINA-007 | Start Date*: 2012-10-26 |
Sponsor Name:MerLion Pharmaceuticals GmbH | ||
Full Title: A Multi-Dose, Double-Blind, Double-Dummy, Active Control, Randomized Clinical (Phase II) Study of Two Dosing Regimens of Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Requiring... | ||
Medical condition: Complicated Urinary Tract Infection and/or Acute Polyonephritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-004402-10 | Sponsor Protocol Number: APHP180587 | Start Date*: 2020-03-11 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Fecal transplantation to Eradicate Colonizing Emergent Superbugs | |||||||||||||
Medical condition: Patients colonized with MDR-GNB (multi-drug resistant Gram Negative bacteria ) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003772-31 | Sponsor Protocol Number: IT001-302 | Start Date*: 2018-12-07 |
Sponsor Name:Iterum Therapeutics International Limited | ||
Full Title: A prospective, Phase 3, randomized, multi-center, double-blind, double dummy study of the efficacy, tolerability and safety of intravenous sulopenem followed by oral sulopenem-etzadroxil with probe... | ||
Medical condition: Complicated urinary tract infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LV (Completed) HU (Completed) EE (Completed) CZ (Completed) BG (Completed) SK (Completed) HR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-001491-39 | Sponsor Protocol Number: 03-0-192 | Start Date*: 2005-02-16 | |||||||||||
Sponsor Name:Astellas Pharma US, Inc. | |||||||||||||
Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE STUDY OF MICAFUNGIN (FK463) VERSUS CASPOFUNGIN AS ANTIFUNGAL TREATMENT IN PATIENTS WITH INVASIVE CANDIDIASIS OR CANDIDEMIA | |||||||||||||
Medical condition: Invasive candidiasis or candidemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GB (Completed) BE (Completed) AT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002084-26 | Sponsor Protocol Number: MK0991-064 | Start Date*: 2017-01-27 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp. | |||||||||||||
Full Title: A Multicenter, Double-Blind, Randomized, Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasiv... | |||||||||||||
Medical condition: Invasive Candidiasis | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Prematurely Ended) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002192-23 | Sponsor Protocol Number: GS-US-404-1808 | Start Date*: 2016-06-03 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2b, Dose-Ranging Study of the Effect of GS-5745 on FEV1 in Adult Subjects with Cystic Fibrosis | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) BE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003951-18 | Sponsor Protocol Number: WSA-CS-008 | Start Date*: 2007-05-29 | |||||||||||
Sponsor Name:Astellas Global Pharma Development, Inc. | |||||||||||||
Full Title: A phase III, double-blind, randomized study to evaluate the safety and efficacy of BAL8557 versus a Caspofungin followed by Voriconazole regimen in the treatment of candidemia and other invasive Ca... | |||||||||||||
Medical condition: Treatment of Candidemia and other invasive Candida infections | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) HU (Completed) ES (Completed) NL (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003792-19 | Sponsor Protocol Number: FOS-PROST-001 | Start Date*: 2021-03-04 |
Sponsor Name:Hospital Universitari Mutua Terrassa | ||
Full Title: Fosfomycin as an oral alternative treatment for acute bacterial prostatitis due to multi-drug resistant Escherichia coli. Pilot study | ||
Medical condition: Acute bacterial prostatitis due to multi-drug resistant Escherichia coli | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-003446-45 | Sponsor Protocol Number: TBTCS31/A5349 | Start Date*: 2016-02-25 |
Sponsor Name:Unidad de investigación en Tuberculosis de Barcelona | ||
Full Title: Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial | ||
Medical condition: Pulmonary tuberculosis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004261-10 | Sponsor Protocol Number: AR-105-002 | Start Date*: 2017-10-19 | |||||||||||
Sponsor Name:Aridis Pharmaceuticals, Inc. | |||||||||||||
Full Title: Placebo-controlled, double-blind, randomized study of Aerucin® as adjunct therapy to antibiotics in the treatment of P. aeruginosa pneumonia | |||||||||||||
Medical condition: Pseudomonas aeruginosa pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Prematurely Ended) CZ (Completed) HU (Completed) ES (Completed) GR (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003369-20 | Sponsor Protocol Number: CT-P59_3.2 | Start Date*: 2020-11-13 | |||||||||||
Sponsor Name:Celltrion, Inc | |||||||||||||
Full Title: A Phase 2/3, Randomized, Parallel-group, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination with Standard of Care in Outpatients with Severe Acute R... | |||||||||||||
Medical condition: SARS CoV 2 infection in outpatients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) RO (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001857-29 | Sponsor Protocol Number: V130_14 | Start Date*: 2019-03-13 | |||||||||||
Sponsor Name:Seqirus UK Limited | |||||||||||||
Full Title: A Phase III, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus' Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to... | |||||||||||||
Medical condition: Prophylaxis of influenza virus infection | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) EE (Completed) CZ (Completed) LV (Completed) PL (Completed) Outside EU/EEA RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000850-36 | Sponsor Protocol Number: 201600136 | Start Date*: 2017-05-01 |
Sponsor Name:Archivel Farma S.L. | ||
Full Title: Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Investigate the Safety and Immunogenicity of RUTI® Therapeutic Vaccination in Patients with Multi-Drug Resistant Tuberculos... | ||
Medical condition: The medical condition to be investigated is culture-confirmed Multidrug-resistant tuberculosis, i.e. tuberculosis resistant to the two first-line drugs Rifampicin and Isoniazid | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-005599-51 | Sponsor Protocol Number: CD101.IV.2.03 | Start Date*: 2016-09-26 | |||||||||||
Sponsor Name:Cidara Therapeutics Inc. | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-blind Study of the Safety, Tolerability, and Efficacy of CD101 Injection vs Intravenous Caspofungin Followed By Oral Fluconazole Step-down in the Treatmen... | |||||||||||||
Medical condition: Candidemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) GR (Completed) HU (Completed) BG (Completed) BE (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000243-87 | Sponsor Protocol Number: PC_ASP_003 | Start Date*: 2018-11-19 | |||||||||||
Sponsor Name:Pulmocide Ltd | |||||||||||||
Full Title: An open-label study to assess the safety, pharmacokinetics and pharmacodynamics of inhaled PC945 in adult Cystic Fibrosis (CF) patients with persistent pulmonary Aspergillus fumigatus infection. | |||||||||||||
Medical condition: Pulmonary aspergillosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005583-25 | Sponsor Protocol Number: COLIMERO | Start Date*: 2014-07-16 |
Sponsor Name:Consorci Parc de Salut Mar de Barcelona | ||
Full Title: Multicenter, randomized, open label, controlled clinical trial that compares the efficacy of the combination of colistin and meropenem versus monotherapy for the treatment of bacteremia and pneumon... | ||
Medical condition: Bacteriemia and Pneumonia due to Pseudomonas aeruginosa | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2007-006228-36 | Sponsor Protocol Number: LT1225-PII-03/06 | Start Date*: 2008-01-24 | |||||||||||
Sponsor Name:Laboratoires Théa | |||||||||||||
Full Title: Evaluación de la Eficacia y Seguridad de Azyter® (T1225) en la Profilaxis Antibiótica Perioperatoria (descontaminación de la superficie ocular) para la Cirugía de Catarata | |||||||||||||
Medical condition: Profilaxis Antibiótica Perioperatoria (descontaminación de la superficie ocular) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
